February 27, 2024 – Aktiia, the Swiss HealthTech innovator
behind the world’s first wrist-worn 24/7 optical blood pressure monitoring device,
announced the completion of a CHF 27 million (USD 30M) funding round, led by
Redalpine with participation from an international investor syndicate including Khosla
Ventures, Molten, Translink Capital, Verve, and 415 Capital. This strategic infusion of
capital will accelerate Aktiia’s mission to ease the global burden of hypertension by
providing groundbreaking insights into blood pressure management through AI-driven
technology, currently used by over 60,000 customers and dozens of healthcare
organizations.
In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new
President and Board Member. Daniel, a seasoned technology executive with a
distinguished career at companies like Uber and Google, brings a wealth of experience
in entrepreneurship, product innovation, and scaling businesses. His leadership will be
instrumental in guiding Aktiia’s strategic direction and expansion as the company
continues to pioneer advancements in hypertension management.
“Aktiia’s commitment to transforming the way blood pressure is treated and understood
aligns perfectly with my passion for leveraging technology to address pressing
healthcare challenges,” said Daniel Graf. “I am excited to join this talented team and
contribute to a future where hypertension management is more proactive, data-driven,
personalized, and effective.”
Aktiia’s CE-marked device is currently available in seven European markets and
approved as a medical device in 44 countries worldwide. Built on 20+ years of research,
Aktiia’s technology provides unparalleled innovation and ease in blood pressure data
collection and machine learning modeling, offering personalized, continuous, and
medical-grade blood pressure and heart rate data. Aktiia empowers people,
researchers, and clinicians with unique blood pressure data paving the way for novel
understanding and personalized patient care of hypertension.
With over 300 million data points from across the globe, Aktiia’s continuous blood
pressure dataset is growing exponentially, creating countless opportunities for deep
learning on public health trends and patterns to advance our understanding of blood
pressure, to provide predictive insights on a global scale. “We are proud to have Daniel join our board and executive team,” said Mattia Bertschi, CEO of Aktiia. “His expertise in scaling innovative technologies will be invaluable as we continue to expand our reach and impact in the global healthcare market. The infusion of new capital from a stellar group of visionary investors is a testament to the confidence our partners have in our technology, and we are excited to accelerate our efforts to revolutionize hypertension management.”
Aktiia’s mission has never been more critical, with over 1.4 billion people worldwide
affected by high blood pressure, resulting in more than 18 million related deaths
annually. The company is dedicated to changing the paradigm of blood pressure
management, making it more accessible, accurate, and actionable for people
worldwide.